Developing an AI-based diagnostic algorithm for early colon cancer detection
20 September 2019 | news
BioLizard and Novigenix sign a collaboration agreement to develop an AI-based diagnostic algorithm for early colon cancer detection.
We're excited to announce that we will be collaborating with Novigenix SA to develop an artificial intelligent-based clinical diagnostic algorithm to support the transition of the company’s first Immuno-Transcriptomic RT-PCR based product for early colon cancer detection “Colox®” onto the next generation platform LITOseek. Novigenix is a healthcare company with a mission to improve early detection of cancer and increase survival rates. They are committed to unravelling complex interactions of host immune responses to cancer by utilising novel immuno-transcriptomic technology. BioLizard will aid in the transition of their existing Colox immuno-transcriptomic RT-PCR product onto a new NGS-based platform, LITOseek.
NOVIGENIX NEXT GENERATION TECHNOLOGY: LITOseek™
Seek biomarkers from liquid-based immuno-transcriptomic profiling of immune cells
(Image taken from novigenix.com.)
We will use our extensive expertise in bioinformatics, machine learning, artificial intelligence and data mining to co-develop a unique proprietary clinical diagnostic algorithm for Novigenix LITOseek platform. The LITOseek platform makes use of disease specific gene expression modifications (mRNA signatures) found in blood samples combined with artificial intelligence based algorithms to predict onset and progression of colon cancer. We will co-develop disease specific algorithms integrating mRNA signatures with additional clinical and medical data. Combining mathematical models and machine learning tools we can enable continuous adaptation and improvement of these learning algorithms.
“We’re proud to collaborate with Novigenix which is developing innovative tests for early cancer detection and therapy monitoring,”
– Dr. Gerben Menschaert
“Partnering with BioLizard helps us to fast track the development of our LITOseek platform,” said Dr. Jan Groen, CEO of Novigenix in a recent interview. “Our current Colox customers will strongly benefit from this new development once we launch our new colon cancer test on the LITOseek platform, but it will also fast track the progress of new products that are currently in the pipeline.”
Read more about the press release here.
Written by Kathryn Morrissey for BioLizard.